Better Science, Better Health
“Better Science, Better Health” was established by Vital Transformation to facilitate international collaboration in new clinical regulatory pathways, sources of evidence, and harnessing real world data to improve the access of needed new medicines by patients.
“Better Science, Better Health” provides a unique opportunity for international thought leaders to engage directly in these initiatives around the world, while also bringing new relevant voices into the process.
“Better Science, Better Health” has three core areas of focus:
- Harnessing real world evidence for better decision-making and create better patient outcomes
- Implementing new development pathways and evidence generation to improve access to needed new therapies for patients
- Developing best practices, successes, and opportunities for the integration of patient data and analytics to identify new medicines
Latest Events
Strategic Medicare Contracting Forum – Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
21 November 2019 2.15pm ET
Vital Transformation has conducted two studies examining the impact of the proposed international reference pricing in Medicare Part D on the world-class innovative biotechnology sector in California and the United States.
Webinar: International Reference Pricing – A Failed Strategy for Patients and Innovation?
23rd of October 13.00-14.00 Eastern US
This webinar presents original research by Vital Transformation that will be peer review published in Therapeutic Innovation and Regulatory Science, showing the devastating impact on R&D, Investments, and patients that will be caused by reference pricing in the United States.
Webinar: RWE, CAR-T and Cancer – New Methods for Comparative Effectiveness
With the increasing use of new regulatory tools, like the FDA’s breakthrough therapy designation, there are increasing demands for European health technology assessors (HTAs) to make an accurate assessment of the long-term value and performance of CAR-T therapies from smaller datasets and shorter outcomes. This webinar will highlight our recent publication in the BMJ, sponsored by ZIN, which showcases a novel approach to harnessing RWE and develops a longitudinal data set that can be used for effectiveness measures, even in orphan conditions. As well, we will kickoff our new research project in Diffuse large B-cell lymphoma (DLBCL) and describe how we will leverage our methodology to measure the effectiveness of the various options for treatment, both in emerging CAR-T treatments, as well as existing chemotherapy regimes and bone-marrow transplants.
Latest News
EHFG: CAR-T: The evolution of a revolution?
Do CAR-T – Chimeric antigen receptor T-cell – therapies have the potential to revolutionise cancer care? These therapies are disrupting traditional concepts of immuno-oncology, manufacturing, delivery and value across Europe. However, for many, there remain a number of open questions that need to be addressed. This session highlighted the transformative potential of these therapies, and sceptical voices who will focus on the unknown variables and where current challenges lie.
Health care 2024: Privacy in the age of digital medicine
Duane Schulthess, managing Director of Vital Transformation, was invited as an expert by POLITICO to participate in “Health Care 2024,” a survey-driven series of online debates in which POLITICO will explore how the European Union can best tackle health policy. In this installment of Health Care 2024 POLITICO asks: Can the EU gain benefits from sharing health data without weakening privacy — and if so, how?
Podcast Better Science, Better Health: Erik Tambuyzer Negotiated the First EU Orphan Drug Legislation
Erik Tambuyzer is one of the world’s thought leaders in orphan drugs and rare disease indications. While he was Genzyme’s EU and International Senior Vice-President for Corporate Affairs, he was also the industry’s negotiation lead with the European Commission and Parliament on the Orphan Medicinal Products Regulation, introduced in the year 2000, working together with patients’ organisations and academics.
Newsletter
Register now to receive all the latest news and events.
Latest Research
Our consultancy services
Tweets by BSBHbyVT 
Videos
Visit our youtube channel to view all of our videos.